Pharmaceutics (Mar 2020)

Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant

  • Sayami Ito,
  • Sachiko Hirobe,
  • Takuto Kawakita,
  • Mio Saito,
  • Ying-Shu Quan,
  • Fumio Kamiyama,
  • Ken J. Ishii,
  • Mizuho Nagao,
  • Takao Fujisawa,
  • Masashi Tachibana,
  • Naoki Okada

DOI
https://doi.org/10.3390/pharmaceutics12030267
Journal volume & issue
Vol. 12, no. 3
p. 267

Abstract

Read online

Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin.

Keywords